市場調查報告書
商品編碼
1371892
到 2030 年人工關節市場預測:按類型、材料、用途和地區進行全球分析Artificial Joints Market Forecasts to 2030 - Global Analysis By Type (Non Cemented Artificial Joints, Cemented Artificial Joints and Other Types), Material, Application and By Geography |
根據Stratistics MRC的數據,2023年全球人工關節市場規模為215.3億美元,預計到2030年將達到336.2億美元,預測期內年複合成長率為6.6%。
關節假體,也稱為人工關節或關節移植,是醫療設備。這些設備的設計類似於自然關節,可增加關節活動度、減輕疼痛並恢復身體功能。人工關節經常用於整形外科手術,例如關節重建,以取代因類風濕性關節炎、關節退化和關節外傷等疾病而嚴重受損的關節。
根據美國國家醫學圖書館的數據,到 2022 年,美國全膝關節置換術(TKA) 的需求預計將比 2005 年至 2030 年增加 673%,年度進行 528 萬例全膝關節置換術。
提高對關節健康和可用治療方法的認知並改善患者教育,鼓勵個人及時接受醫療干涉和關節重建手術。此外,隨著世界人口高齡化,骨關節炎和類風濕性關節炎等關節相關疾病的患病不斷增加,推動了對關節重建和人工關節的需求。
儘管多年來人工關節已經有所改善,但它們並不是永久的解決方案。大多數人工關節的使用壽命有限,患者可能需要進行翻修手術,這可能既昂貴又乏味。此外,關節重建手術也有其自身的風險,包括感染疾病、血栓和麻醉併發症,這可能會阻止一些患者選擇這種手術。
材料、植入物設計和手術技術的不斷進步為開發更耐用、更有效率和創新的義肢關節產品提供了機會,這些產品可以改善患者的治療效果。此外,在預測期內,這些地區對關節重建和人工關節的需求可能會增加,使製造商能夠開拓醫療保健需求不斷成長的新興市場。
嚴格的法規要求和核准流程可能會延遲新義肢產品的推出並增加開發成本。此外,與關節假體相關的不利事件或安全問題的報告可能會削弱患者的信心,並導致對關節假體產品的需求減少。這些限制阻礙了市場的擴張。
由於供應鏈中斷和擇期手術延遲,COVID-19 大流行最初擾亂了關節置換市場。然而,隨著手術的恢復,市場逐漸復甦,導致手術積壓。這種流行病可能會加速遠端醫療的採用,影響患者的諮詢和後續護理。由於高齡化對人工關節的持續需求以及醫療技術和研究的持續進步,長期預測仍然樂觀。
水泥人工關節在 2022 年擁有最大的市場佔有率,預計在預測期內將保持其地位。骨水泥關節具有彈性、穩定且牢固地固定在骨骼上。此外,生物相容性高的陶瓷材料和陶瓷含量高的假體關節可以減少關節摩擦和磨損。這些因素在預測期內促進了該領域的成長。
由於膝骨關節炎患病不斷上升以及全膝關節關節重建數量不斷增加,預計膝關節假體部分在預測期內將出現最高成長。此外,人口高齡化和肥胖率上升等要素患病了骨質疏鬆症和關節炎等與老齡化相關的肌肉骨骼疾病的盛行率,也置換術的主要要素。對外科手術和相應植入物的需求推動了該領域的成長。
預計北美地區將在整個預期期間繼續主導市場。該地區最大的兩個經濟體美國和加拿大是該地區市場價值的主要收益。骨關節炎患者數量的增加和高齡化是推動北美市場擴張需求最高的兩個主要因素。此外,由於電腦輔助植入物設計、機器人手術和有利的報銷條款的使用增加,預計美國人工關節市場在預測期內將得到提振。
隨著膝關節疾病變得更加普遍、醫療旅遊蓬勃發展、可支配所得增加以及該地區醫療基礎設施的穩步改善,亞太市場將在預測期內快速成長。此外,人口老化和骨關節炎的患病正在增加。骨關節炎患者數量預計將增加,人工關節和關節重建的需求也預計將增加。因此,這些要素預計將推動亞太地區人工關節市場的開拓。
According to Stratistics MRC, the Global Artificial Joints Market is accounted for $21.53 billion in 2023 and is expected to reach $33.62 billion by 2030 growing at a CAGR of 6.6% during the forecast period. Artificial joints, also known as prosthetic joints or joint implants, are medical gadgets designed to replace a human body joint that has been damaged or is aging. These devices are made to function like a natural joint would, enhancing joint mobility, reducing pain, and regaining physical function. Artificial joints are frequently used in orthopedic procedures like joint replacement surgeries to replace joints that have suffered severe damage from diseases like osteoarthritis, rheumatoid arthritis, joint degeneration, or joint trauma.
According to, National Library of Medicine, in 2022, the demand for total knee arthroplasty (TKA) in the U.S. was anticipated to increase 673% from 2005 to 2030, with 5.28 million TKAs to be done annually.
Growing awareness about joint health and available treatment options, as well as improved patient education, encourages individuals to seek timely medical intervention and joint replacement surgeries. Additionally, as the global population continues to age, the prevalence of joint-related conditions like osteoarthritis and rheumatoid arthritis increases, driving the demand for joint replacement surgeries and artificial joints.
While artificial joints have improved over the years, they are not permanent solutions. Most joints have a limited lifespan, and patients may require revision surgeries, which can be costly and complicated. In addition to that joint replacement surgeries come with inherent risks, including infection, blood clots, and anesthesia complications, which can deter some patients from opting for the procedure.
Ongoing advancements in materials, implant design, and surgical techniques offer opportunities for the development of more durable, efficient, and innovative artificial joint products that can improve patient outcomes. Moreover, manufacturers can tap into emerging markets with growing healthcare needs, as these regions may experience increased demand for joint replacement surgeries and artificial joints over the forecast period.
Stringent regulatory requirements and approval processes can delay the introduction of new artificial joint products and increase development costs. In addition, reports of adverse events or safety concerns related to artificial joints can erode patient trust and lead to reduced demand for these products. Such limitations hinder the market expansion.
The COVID-19 pandemic initially disrupted the artificial joints market due to supply chain disruptions and postponed elective surgeries. However, the market rebounded as surgeries resumed, creating a backlog of procedures. The pandemic accelerated the adoption of telehealth, potentially impacting patient consultations and follow-up care. Long-term prospects remain positive due to an aging population's sustained demand for joint replacements, coupled with ongoing advancements in medical technology and research.
The market's largest share was held by the cemented joints segment in 2022, and it is anticipated that it will hold that position throughout the forecast period. Joints made of cement are more elastic, stable, and securely attached to the bones. Additionally, biocompatible ceramic materials and artificial joints with a high ceramic content can lessen joint friction and wear. Such elements contribute to the segment's growth over the course of the forecast period.
Due to the rising prevalence of knee osteoarthritis and the rising number of knee replacement surgeries, the artificial knee joint segment is anticipated to experience the highest growth over the course of the forecast period. In addition, factors like the aging population, which is increasing the prevalence of age-related musculoskeletal conditions like osteoporosis and arthritis, and the rising obesity rate are all significant drivers of the demand for knee and hip replacement surgeries and the corresponding implants, which is boosting the segment's growth.
The North American region is expected to continue to dominate the market throughout the anticipated period. The two largest economies in the area, the U.S. and Canada, are the main revenue generators for the market value in the area. An increase in osteoarthritis patients and an aging population are the two primary factors that are most likely to increase demand for market expansion in North America. Additionally, it is anticipated that the U.S. artificial joints market will be fueled by an increase in the use of computer-aided implant designs, robotic surgery, and favorable reimbursement conditions over the course of the projection period.
As knee disorders are becoming more prevalent, medical tourism is booming, disposable income is rising, and the healthcare infrastructure in this region is steadily improving, the Asia Pacific market is predicted to grow quickly over the forecasted period. Additionally, there is a rise in geriatric populations and osteoarthritis prevalence. The number of people with osteoarthritis is expected to rise, as will the demand for artificial joints and arthroplasty surgeries. Thus, it is anticipated that these factors will fuel the development of the artificial joint market in Asia-Pacific.
Some of the key players in Artificial Joints market include: Zimmer Biomet Holding Inc, Conformis Inc, Smith & Nephew plc, Stryker Corporation, B. Braun Melsungen AG, Medtronic plc, Johnson and Johnson, Exactech, Medacta International SA and MicroPort Orthopedics Inc.
In June 2023, BioMed X has announced that it has begun a joint research project with Sanofi on artificial intelligence (AI)-driven drug development. The two companies initially announced their partnership late last year, and are now ready to begin work on their AI drug discovery platform. The "Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates" (VPE) project aims to develop a computational platform capable of predicting the efficacy of first or best-in-class drug candidates.
In August 2023, Corentec, a company specializing in the production of artificial joints, announced that the inaugural surgery involving its patient-specific implant (PSI) designed for artificial shoulder joints was effectively carried out at Kyungpook National University Hospital in Korea.